Autoimmune comorbidity in achalasia patients

2017 ◽  
Vol 33 (1) ◽  
pp. 203-208 ◽  
Author(s):  
Fernanda Romero-Hernández ◽  
Janette Furuzawa-Carballeda ◽  
Gabriela Hernández-Molina ◽  
Edgar Alejandro-Medrano ◽  
Carlos A Núñez-Álvarez ◽  
...  
Keyword(s):  
Autoimmune Comorbidity

Autoimmune Comorbid Conditions in Multiple Sclerosis

US Neurology ◽  
2011 ◽  
Vol 07 (02) ◽  
pp. 132 ◽  
Author(s):  
Regina Berkovich ◽  
Dawood Subhani ◽  
Lawrence Steinman ◽  
◽  
◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Autoimmune Disease ◽  
Autoimmune Diseases ◽  
Genetic Susceptibility ◽  
Interferon Beta ◽  
Comorbid Conditions ◽  
Factors Influencing ◽  
Immune Mediated ◽  
Autoimmune Conditions ◽  
Autoimmune Comorbidity

Autoimmune comorbidities occur frequently in multiple sclerosis (MS). They may arise as a consequence of a genetic susceptibility to autoimmunity. Certain pathological mechanisms are common to several autoimmune conditions. In the presence of comorbid autoimmune conditions, certain MS therapeutics may be preferable to others. Autoimmune comorbidity associated with MS could be a factor in predicting response to specific MS therapeutics. Treatment with interferon beta has been reported to precipitate immune-mediated abnormalities or to exacerbate existing autoimmune diseases. In comparison, there are fewer reported cases of treatment-associated comorbidities linked with autoimmune disease in patients taking glatiramer acetate. Knowledge of the factors influencing autoimmune comorbidities may provide insights into the complex pathogenesis of MS and help inform treatment choices.

The Effect of Isotretinoin on Vitiligo and Autoimmune Comorbidity

2020 ◽  
Vol 19 (6) ◽  
pp. 637-638
Author(s):  
Megan O’Connor ◽  
Jonathan Silverberg ◽  
Nanette Silverberg
Keyword(s):  
Autoimmune Comorbidity

scholarly journals DNA hydrolysing IgG catalytic antibodies: an emerging link between psychoses and autoimmunity

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Rajendran Ramesh ◽  
Aparna Sundaresh ◽  
Ravi Philip Rajkumar ◽  
Vir Singh Negi ◽  
M. A. Vijayalakshmi ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Psychotic Disorders ◽  
Catalytic Antibodies ◽  
Dnase Activity ◽  
Study Group ◽  
Healthy Controls ◽  
Systemic Lupus ◽  
Similar Activity ◽  
Polyclonal Igg ◽  
Autoimmune Comorbidity

AbstractIt is not uncommon to observe autoimmune comorbidities in a significant subset of patients with psychotic disorders, namely schizophrenia (SCZ) and bipolar disorder (BPD). To understand the autoimmune basis, the DNA abyzme activity mediated by serum polyclonal IgG Abs were examined in psychoses patients, quantitatively, by an in-house optimized DNase assay. A similar activity exhibited by IgG Abs from neuropsychiatric-systemic lupus erythematosus (NP-SLE) patients was used as a comparator. Our data revealed that the IgG DNase activity of SCZ was close to that of NP-SLE and it was twofold higher than the healthy controls. Interestingly, the association between DNase activity with PANSS (positive, general and total scores) and MADRS were noted in a subgroup of SCZ and BPD patients, respectively. In our study group, the levels of IL-6 and total IgG in BPD patients were higher than SCZ and healthy controls, indicating a relatively inflammatory nature in BPD, while autoimmune comorbidity was mainly observed in SCZ patients.

scholarly journals Diagnosis of sleepiness, fatigue and depression in patients with myasthenia gravis

2020 ◽  
Vol 10 (4) ◽  
pp. 27-37
Author(s):  
O. A. Kreis ◽  
T. M. Alekseeva ◽  
Yu. V. Gavrilov ◽  
P. O. Valko ◽  
Yu. Valko
Keyword(s):  
Myasthenia Gravis ◽  
Excessive Daytime Sleepiness ◽  
Daytime Sleepiness ◽  
Fatigue Severity Scale ◽  
Severity Scale ◽  
Impact Scale ◽  
Fatigue Severity ◽  
Autoimmune Comorbidity ◽  
Fatigue Impact Scale ◽  
The Impact

Introduction. Examination of excessive daytime sleepiness, fatigue and depression in patients with myasthenia gravis is important for differential diagnosis of other disorders, and adds to a comprehensive clinical assessment.Objective. The aim is a comprehensive assessment of sleepiness, fatigue and depression and evaluation of the impact of autoimmune comorbidity on these symptoms in myasthenia gravis patients, using newly validated Russian versions of international questionnaires. The present article aims at familiarizing a wider Russian-speaking audience of specialists in the field of neuromuscular disease and sleep medicine with the main findings of our previously published work.Materials and methods. The study included 73 patients with MG and 230 control subjects. For sleepiness, fatigue and depression evaluation were used: Fatigue Severity Scale (FSS), Fatigue Impact Scale (FIS) (cognitive / physical / psychosocial subscales), Epworth Sleepiness Scale (ESS), Beck Depression Inventory (BDI) (cognitive-affective and somatic domains), Spielberger–Khanin State Trait Anxiety Inventory (STAI).Results. The Fatigue Severity Scale and Fatigue Impact Scale showed good psychometric properties and can be used to identify distinct aspects of fatigue in patients with myasthenia gravis. The studied patient cohort revealed clinically significant fatigue (69.9 %), excessive daytime sleepiness (15.1 %), moderate to severe depression (20.5 %), a high level of personal (64.4 %) and situational anxiety (27.4 %). Among 13 patients with myasthenia gravis and additional autoimmune comorbidity, there were no significant differences in the severity of sleepiness, fatigue and depression compared with the main group.Conclusion. The use of self-reported scale of sleepiness, fatigue and depression combined with careful clinical-neurological characterization adds to a more comprehensive view of the patient. The identification of sleepiness, fatigue and depression can guide therapeutic decisions and contributes to a better patient care. The presence of concomitant autoimmune pathology in patients with myasthenia gravis does not seem to increase the severity of sleepiness, fatigue and depression.

Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review

2017 ◽  
Vol 16 (12) ◽  
pp. 1196-1208 ◽  
Author(s):  
Pavel Kolkhir ◽  
Elena Borzova ◽  
Clive Grattan ◽  
Riccardo Asero ◽  
Dmitry Pogorelov ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Spontaneous Urticaria ◽  
Autoimmune Comorbidity

Gender and autoimmune comorbidity in multiple sclerosis

2014 ◽  
Vol 20 (9) ◽  
pp. 1244-1251 ◽  
Author(s):  
Melinda Magyari ◽  
Nils Koch-Henriksen ◽  
Claudia C Pfleger ◽  
Per Soelberg Sørensen
Keyword(s):  
Multiple Sclerosis ◽  
Lupus Erythematosus ◽  
Odds Ratio ◽  
Type I Diabetes ◽  
Type I ◽  
National Patient Register ◽  
Clinical Onset ◽  
National Patient ◽  
Autoimmune Comorbidity ◽  
Danish National Patient Register

Background: The female preponderance in incidence of multiple sclerosis (MS) calls for investigations into sex differences in comorbidity with other autoimmune diseases (ADs). Objectives: To determine whether male and female patients with MS have a higher frequency of autoimmune comorbidity than controls, and to describe the type and frequency of ADs that are associated with MS. Methods: Our database was established by linkage of the Danish MS Registry to The Danish National Patient Register and consisted of 1403 patients of both sexes with clinical onset of MS between 2000 and 2004, and 25 matched controls for every case. Results: None of the ADs occurred more frequently in female cases than in controls. Male cases were more likely to have Type I diabetes mellitus (odds ratio (OR) = 3.34; 95% CI 1.40 – 7.02; p < 0.008), Crohn’s disease (OR = 5.03; 95% CI 1.18 – 16.10; p = 0.03) and systemic lupus erythematosus (OR = 12.55; 95% CI 1.62 – 69.95; p = 0.02) than male controls. Conclusions: Autoimmune disorders are rare, but some of them tend to occur together with MS at a higher rate than in controls. Although women are generally more prone to ADs than men, significantly increased occurrence of other ADs were only found in male MS patients.

scholarly journals Sex-Specific Limitations in Physical Health in Primary Adrenal Insufficiency

2021 ◽  
Vol 12 ◽  
Author(s):  
Nora Møller Didriksen ◽  
Åse Bjorvatn Sævik ◽  
Linn Solveig Sortland ◽  
Marianne Øksnes ◽  
Eystein Sverre Husebye
Keyword(s):  
Adrenal Insufficiency ◽  
Social Functioning ◽  
Normative Data ◽  
Clinical Characteristics ◽  
Large Scale ◽  
Primary Adrenal Insufficiency ◽  
Cross Sectional ◽  
Physical Role ◽  
Autoimmune Comorbidity ◽  
Autoimmune Etiology

BackgroundPatients with primary adrenal insufficiency (PAI) suffer reduced quality of life (QoL), but comparisons with large-scale normative data are scarce. The clinical characteristics associated with reduced QoL are largely unknown.MethodsCross-sectional data on clinical characteristics and QoL scores from 494 patients were included. QoL was measured using RAND-36 (generic) and AddiQoL (-30 and -8, disease-specific). RAND-36 is reported as subdomain scores as well as physical (PCS) and metal (MCS) summary scores and compared with normative data.ResultsPerception of physical role was consistently decreased across age groups in patients with PAI compared with normative data [75 (0-100) vs. 100 (50-100), p&lt;0.001]. Men with PAI reported significantly lower scores for social functioning [88 (75-100) vs. 100 (75-100), p&lt;0.001], as well as for vitality and physical role. In women, the greatest impairment was seen in physical role [50 (0-100) vs. 100 (50-100), p&lt;0.001], followed by social functioning, vitality, physical function, general health, mental health, and emotional role. Overall, better QoL was associated with male sex (AddiQoL-30: 89 ± 13 vs. 82 ± 13, p&lt;0.002), younger age (e.g. 20-29 vs. 80-89 years: PCS 59 [50-62] vs. 46 [37-53], p&lt;0.001), autoimmune etiology [PCS: 53 (45-59) vs.. 45 (38-54), p&lt;0.001], and absence of autoimmune comorbidity [PCS: 54 (45-59) vs. 50 (43-58), p&lt;0.001]. There were no significant differences in QoL scores between different doses or dosing regimens of glucocorticoid or mineralocorticoid replacement.ConclusionQoL is reduced in patients with PAI, especially perception of physical role in women and social functioning in men. Among patients with PAI, female sex, higher age, non-autoimmune etiology, and autoimmune comorbidity was associated with lower QoL-scores.

Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis

2019 ◽  
Vol 266 (8) ◽  
pp. 2027-2034 ◽  
Author(s):  
T. M. Alekseeva ◽  
O. A. Kreis ◽  
Y. V. Gavrilov ◽  
P. O. Valko ◽  
K. P. Weber ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Autoimmune Comorbidity

Genetic contributors and soluble mediators in prediction of autoimmune comorbidity

2019 ◽  
Vol 104 ◽  
pp. 102317
Author(s):  
Adrianos Nezos ◽  
Maria-Eleutheria Evangelopoulos ◽  
Clio P. Mavragani
Keyword(s):  
Autoimmune Comorbidity
Sign in / Sign up

Export Citation Format

Share Document